In large part, the success with the iPhone in recent years was fueled by the release of larger handsets, starting with the iPhone 6 series, with one model at 4.7 niches and a “Plus” variant at 5.5 inches. Supposedly, then, all iPhone uses were expected to adapt.
But that’s not quite how things worked out. There are still many users who don’t want the larger displays an the difficulties involved in single-handed use. This is why Apple came out with the iPhone SE in 2016, which had most of the features and performance of the iPhone 6s installed in what was essentially the case of an iPhone 5s.
Although there has been speculation about an iPhone SE2, with specs matching the more recent models, it hasn’t happened. As of last week’s announcements about a new iPhone lineup, the SE has been removed from the lineup, with no word on when or if a replacement will come.
This isn’t to say the iPhone SE is a bad phone, or necessarily obsolete. Sure, it doesn’t have Face ID, but it’s small, slim, lightweight and more than enough phone for many people. With iOS 12, performance is more than sufficient to satisfy most people, so why did Apple bid it farewell?
For several years, Mrs. Steinberg made do with an iPhone 5c because it fit comfortably into her tiny purses. A larger iPhone would be a squeeze, but a closeout SE might be just the ticket for her if they can be found. Let’s face it, her present iPhone is obsolete, being saddled with iOS 10, and it feels mighty sluggish compared to more recent models. It also became a problem when we stayed at a motel where reception on the AT&T network wasn’t so good, which meant that she’d miss half the calls, because they’d go to voicemail.
Will Apple reconsider an SE successor? If there was a market for it, perhaps. But it may just be that sales of the existing model, available for $349 (the cheapest iPhone ever), just didn’t sell terribly well.
This weekend, we presented a thorough look at tech, microchip credit cards, and identity theft with credit repair specialist Darius Norman, author of “Rewriting Financial Rules.” Following the introduction of microchip equipped credit cards in 2015 in the United States, which make the cards difficult to counterfeit, criminals focused on new forms of account fraud. We are also seeing thieves going after our children’s social security numbers to do this, so our children are in danger and may never know until they are old enough to apply for credit themselves. What do we do? Darius also focused on what you should do in the event your credit history or identity are compromised, as Gene revealed some of his personal experiences.
You also heard from tech editor Bryan Chaffin, co-founder and co-publisher of The Mac Observer. During this segment, Bryan talked at length about Apple’s September 12th media event, in which three new iPhone X variants were demonstrated. Bryan covered his experiences in ordering one of the new smartphones, plus an Apple Watch Series 4. As a long-time user of luxury watches, Bryan related his experience with an Apple Watch Series 2 and his expectations for the Series 4, which includes more health-related features, such as an ECG to measure the health of your heart. There was also some talk about iOS 12. which was released on September 17th.
On this week’s episode of our other radio show, The Paracast: Gene and Randall presented Bryan Bonner of the Rocky Mountain Paranormal Research Society. For over two decades Bryan, with a healthy dose of skepticism, has examined a wide range of reported paranormal phenomena, including ghosts, poltergeists, psychics, UFOs, conspiracy theories, urban legends, and much more. Unlike others in the field, Bryan has made sure not to run around cemeteries, screaming and scaring the group with overactive imaginations. From the field to the lab, he tests bizarre beliefs and practices, conducts experiments and on-site investigations, and recreates unusual events. He has confronted hauntings, Ouija board activity, levitation, psychic readings, alien abductions, and telephones that try to talk to the dead.
A PREDICTABLE APPLE MEDIA EVENT WITH A PREDICTABLE OUTCOME
In the run-up to Apple’s September 12th media event last week, there was speculation aplenty. But most of it coalesced on three new iPhones and an Apple Watch Series 4, the new operating systems under test since June — and not much else.
This is not to say that Apple’s announcements were disappointing. The new products are tempting, particularly one reasonably affordable iPhone that I’ll mention shortly. But it may well be that the Apple Watch Series 4 turned out to be the star of the show.
But I’m getting ahead of myself.
So as predicted, there are three new iPhones fashioned after last year’s iPhone X. Typical of Apple’s mostly usual approach, there’s the tick-tock pattern. The brand new design one year, the minor refresh the next.
So this year, the iPhone X was replaced with the iPhone XS. Despite predictions that it would be $100 cheaper, it remains at $999. Based on Apple’s report that it has been the best-selling smartphone on the planet for months, Apple had no reason to change its pricing strategy.
In addition to the 5.8-inch model, there is a “Plus” model, dubbed iPhone XS Max, which offers a 6.5-inch display and retails for $1,099 for the 64GB model. But since Samsung offers a maxed out Galaxy Note9 for $1,249, Apple is not really going overboard, although its maxed out Max costs even more.
Being an “S” model, just what do you get that wasn’t on last year’s iPhone X? Well, there’s of course the A12 Bionic CPU, with the promise of 15% faster performance with 40% greater power efficiency. The four-core graphics processor offers 50% greater performance than its predecessor according to Apple.
But the one feature that has true geek appeal is the fact that the A12 is fabricated on a 7-nanometer manufacturing process, with some 6.9 billion transistors. This comes at the same time that Intel is reportedly encountering problems building chips with a 14-nanometer process. Indeed, I read a story that Intel might actually outsource support to one of Apple’s key CPU makers, TSMC.
There are the usual improvements in camera quality and processing features, along with tougher glass, reputedly Corning Gorilla Glass 6, and improved water- and dust-proofing. More power efficiency means that the iPhone XS will offer the promise of 30 minutes longer battery life; it’s up to an hour and a half more on the iPhone XS Max.
Yet the real star of the new lineup may very well be the 6.1-inch LCD version dubbed iPhone XR. At a starting price of $749, it provides most of the features of its bigger brothers, and the tradeoffs seem sensible enough.
So the new display doesn’t offer HDR, which promises richer colors with the right content, and a single camera rather than two, although there will evidently still be a way to take portrait-style photos. 3D touch is missing in action, as if anyone cares. Also you can only safely dunk it in one meter of water rather than two meters.
But the XR still comes equipped with Face ID and an edge-to-edge display complete with the famous notch. Since it’s also equipped with the A12 CPU, performance should be identical to its big brothers. It also comes with a less expensive case design and a wider choice of colors.
The original iPhone X is gone. The iPhone 7 and iPhone 8 remain in the product lineup at cheaper prices to give customers more options, but there’s nothing to match the $349 iPhone SE.
Assuming the XR’s Liquid Retina display is as good as Apple claims, and you can live with the few tradeoffs, $749 is far friendlier than $999 and up, even if you consider a monthly payment plan. But you’ll have to wait, since it won’t arrive until roughly a month after the rest of the lineup.
Predictions for the Apple Watch Series 4 were quite in line with predictions. It’s slimmer with narrower screen bezels, thus allowing for larger displays. One of the most important health-related features is an FDA-certified electrocardiogram (ECG) sensor. So is the Apple Watch now a Tricorder or does it need some additional health-tracking features to make the grade?
It can also call emergency services you fall and you can’t get up for a minute or longer. Prices start at $399, and the version with an LTE radio is $100 more.
The two OLED iPhones and the Apple Watch Series 4 ship this weekend, and have already garnered mostly positive reviews.
Golden Masters of the various Apple OS upgrades were seeded to developers and public beta testers last week, and final version so everything but macOS Mojave shipped on September 17th. The macOS Mojave upgrade will arrive next week, but the GM should pretty much be it except for a possible last-minute change before the final release.
All in all, Apple did what it expected to do. I can’t say I’m prepared to buy any of the new gear for the time being, but I am using the GMs of iOS 12 and macOS Mojave with mostly good success so far. And, yes, I still have my $12.88 stainless steel Walmart calendar watch. An Apple Watch is not on the horizon for me.
Reports have surfaced that Coca-Cola is eyeing a deal with Aurora Cannabis, which may result in the production of a cannabis-infused cola drink.
The talks between the Canadian cannabis company and the famous Atlanta-based cola corporation was reported by Bloomberg.
Cannabis-infused foods have been a favorite in legalized markets where consumers wish to avoid inhaling the plant.
A legalized market coupled with a high demand for such a beverage could send shares “flying.”
However its safety, such as when mixed with alcohol, raises concerns.
Cannabis plants produce cannabinoids, or chemicals that can induce an effect on the body. When cannabinoids are produced by a plant they are called phytocannabinoids. Humans produce their own cannabinoids, called endogenous cannabinoids. Laboratory or synthetically produced cannabinoids are called synthetic cannabinoids.
The human body has a very intricate endocannabinoid (endogenous cannabinoid) system, with receptors throughout our brain, organs, glands, and immune system. Hence a wide variety of physiological responses, occur when these receptors are stimulated by cannabinoids. These include responses to sleep, memory, appetite, pain, immune response, mood, and cell damage repair and death, Research is currently investigating what endogenous chemicals the human body produces, but the majority of medical discussions surrounding cannabinoids includes the phytocannabinoids.
Cannabis plants produce many phytocannabinoids, but the most well-known and studied include CBD (cannabidiol) and THC (Tetrahydrocannabinol). The latter is psychoactive, meaning it can give the user a feeling of euphoria. The former, CBD, in non-psychoactive and researched more than others for its medicinal benefits.
Now plants, just like animals, are classified from Kingdom (Plantae) down to Genus and species. Cannabis comes in a variety of species, including the major ones: C. sativa, C. indica and C. ruderalis.
C. ruderalis is less popular as it has a lower THC content. However it has “autoflowering” qualities, making them useful to cultivators, and if bred with C. sativa or C. indica could enhance the new hybrid in its reproduction.
C. sativa has a higher THC/CBD ratio, hence can provide more euphoria. It reportedly helps decrease anxiety, treat depression and increase appetite. It’s been touted to increase energy and boost creativity. It's also used to help manage attention deficit disorder. Although not approved yet in the US, an oral spray, nabiximol, has been developed and sold in multiple countries to treat neuropathic cancer pain. Its brand name is sold, by prescription, as Sativex® .
C. indica has a higher CBD content and has been used for its sedative properties. It's also used to help anxiety and induce appetite, but will additionally be used to treat pain and muscle spasms.
Epidiolex has received FDA approval to treat some seizures. Its high CBD component is credited for its anti-seizure activity.
There are multiple other strains, each touted to have their own unique properties. 420medbook.com provides the below table.
The challenge, however, is the lack of medical research in each of the different strains. And when a study does come out discussing the medical advantages or disadvantages to using cannabis medicinally, the specific strain may not be mentioned or easily found in the report.
I believe that various strains do have unique properties and there is an art to the field of medical marijuana but more research needs to be done and quickly to avoid random use of cannabis products for treatment of medical conditions.